RIMED "MOU for Joint Research on Blood-Brain Barrier Penetration Drug Delivery Technology for Brain Diseases"

[Asia Economy Reporter Hyungsoo Park] Remed, a developer of electronic medicine, announced on the 9th that it held consultations on the 8th to conduct joint research with Professor Sangkyu Yesang of Seoul National University College of Medicine, who studies the interaction between cancer cells and immune cells in the tumor microenvironment, and Professor Sangsik Lee of the Department of Medical Engineering at Catholic Kwandong University, an authority in the field of digital therapeutic devices. They will collaborate on research regarding drug delivery technology using rTMS to cross the blood-brain barrier (BBB).

Professors Sangkyu Yesang and Sangsik Lee, who were jointly conducting research on dementia treatment mechanisms and the development of digital electronic medicine, observed results of crossing the BBB in cell and animal experiments. They were able to mechanistically predict the possibility and, based on the research results, held a signing ceremony for joint research on BBB drug delivery with Remed.

Professor Sangkyu Yesang of Seoul National University, the lead researcher, received his Ph.D. in the laboratory of Professor Tasuku Honjo at Kyoto University, who won the 2018 Nobel Prize in Physiology or Medicine for contributions to immune checkpoint inhibitor development. He continues to conduct research for anticancer drug development, including regulation of CD133 expression by STAT3 and development of STAT3-specific inhibitors.

At a seminar sponsored by Remed, discussions were held on the potential and protocols of preclinical preliminary experiments for BBB-crossing brain disease drug delivery technology, as well as brain disease treatment candidate substances that can be integrated with BBB-regulating medical devices.

They agreed to carry out joint research on BBB-crossing drug delivery technology, continuous seminars, and virtuous cycle product development involving medical devices, candidate substances, and new drugs.

The BBB-penetrating drug delivery technology will be expanded into a consultative body composed of experts from industry, academia, hospitals, and government in the future. Regular seminars will be held centered on hospitals that will practically conduct clinical trials, and a global expert group meeting will be established.

Lee Geunyong, Chairman of the Board of Directors at Remed, who led the seminar, said, "Research is important for Remed, a company in the digital electronic medicine field, to emerge as a global leader related to brain diseases," and added, "We will enhance international competitiveness through continuous research investment in line with the government's 4th Industrial Revolution digital New Deal policy."